Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations

Expert Review of Respiratory Medicine

Volumn 11, Issue 1, 2017, Pages 29-40

  Chang, Hun Soo ^a   Lee, Tae Hyeong ^a   Jun, Ji Ae ^a   Baek, Ae Rin ^b   Park, Jong Sook ^b   Koo, So My ^b   Kim, Yang Ki ^b   Lee, Ho Sung ^b   Park, Choon Sik ^b  

^a Soonchunhyang Graduate School   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

Asthma; biologics; HRCT; innate immune response; neutrophilc inflammation; remodeling

Indexed keywords

CIGARETTE SMOKE; ENDOTOXIN; GLUCOCORTICOID; IRRITANT AGENT; OZONE; TOLL LIKE RECEPTOR; INFLAMMASOME;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; HUMAN; MOLECULAR MECHANICS; NEUTROPHILIC INFLAMMATION; PARTICULATE MATTER; RESPIRATORY TRACT INFLAMMATION; REVIEW; TH1 CELL; TH17 CELL; IMMUNOLOGY; INFLAMMATION; NEUTROPHIL; RESPIRATORY SYSTEM;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ASTHMA; HUMANS; INFLAMMASOMES; INFLAMMATION; NEUTROPHILS; RESPIRATORY SYSTEM; TH17 CELLS;

EID: 85006757726     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2017.1268919     Document Type: Review

References (153)

1. Huber HL, Koessler KK., The pathology of bronchial asthma. Arch Intern Med. 1922;30(6):689–760.
2. Rackemann FM. Studies in asthma:I. A clinical survey of 1,074 patients with asthma followed for two years. J Lab Clin Med. 1927;12(Sept):1185.
3. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet (London, England). 1999;353(9171):2213–2214.
4. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma:identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875–879.
5. Anees W, Huggins V, Pavord ID, et al. Occupational asthma due to low molecular weight agents:eosinophilic and non-eosinophilic variants. Thorax. 2002;57(3):231–236.
6. Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma:assessment and identification using induced sputum. Respirology (Carlton, Vic.). 2006;11(1):54–61.
7. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma:evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001;119(5):1329–1336.
8. Green RH, Pavord I. Stability of inflammatory phenotypes in asthma. Thorax. 2012;67(8):665–667.
9. Al-Samri MT, Benedetti A, Prefontaine D, et al. Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy:a prospective study using multiple samples. J Allergy Clin Immunol. 2010;125(5):1161-1163.e4.
10. Kupczyk M, Dahlen B, Sterk PJ, et al. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy. 2014;69(9):1198–1204.
11. Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med. 1996;153(2):551–556.
12. Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol. 2003;112(1):58–63.
13. Saffar AS, Ashdown H, Gounni AS. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets. 2011;12(4):556–562.
14. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;62(12):1043–1049.
15. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma:insights from clinical studies. Proc Am Thorac Soc. 2009;6(3):256–259.
16. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185(6):612–619.
17. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts:a randomised controlled trial. Lancet (London, England). 2002;360(9347):1715–1721.• Absence of sputum eosinophils is a consistent feature over 12 months’ longitudinal observation of patients with severe asthma, indicating the presence of neutrophilic airway inflammation in asthma.
18. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis. 1993;148(3):713–719.
19. Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156(3 Pt 1):737–743.
20. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532–1539.
21. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–1008.
22. Bacci E, Cianchetti S, Bartoli M, et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest. 2006;129(3):565–572.
23. Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557–1563.e1555.
24. Jang AS, Kwon HS, Cho YS, et al. Identification of subtypes of refractory asthma in Korean patients by cluster analysis. Lung. 2013;191(1):87–93.
25. Choi JS, Jang AS, Park JS, et al. Role of neutrophils in persistent airway obstruction due to refractory asthma. Respirology (Carlton, Vic.). 2012;17(2):322–329.• Airway neutrophilia is associated with persistent airflow limitations in patients with refractory asthma, whereas eosinophilic inflammation predominates in patients with reversible airway obstruction.
26. Pietinalho A, Pelkonen A, Rytila P. Linkage between smoking and asthma. Allergy. 2009;64(12):1722–1727.
27. Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226–230.
28. Papaiwannou A, Zarogoulidis P, Porpodis K, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS):current literature review. J Thorac Dis. 2014;6(Suppl 1):S146–151.
29. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD:what are its features and how important is it? Thorax. 2009;64(8):728–735.
30. Nightingale JA, Rogers DF, Barnes PJ. Effect of inhaled ozone on exhaled nitric oxide, pulmonary function, and induced sputum in normal and asthmatic subjects. Thorax. 1999;54(12):1061–1069.
31. Nightingale JA, Maggs R, Cullinan P, et al. Airway inflammation after controlled exposure to diesel exhaust particulates. Am J Respir Crit Care Med. 2000;162(1):161–166.
32. Pavord ID, Birring SS, Berry M, et al. Multiple inflammatory hits and the pathogenesis of severe airway disease. Eur Respir J. 2006;27(5):884–888.
33. Birring SS, Patel RB, Parker D, et al. Airway function and markers of airway inflammation in patients with treated hypothyroidism. Thorax. 2005;60(3):249–253.
34. Reed CE, Milton DK. Endotoxin-stimulated innate immunity:a contributing factor for asthma. J Allergy Clin Immunol. 2001;108(2):157–166.
35. Nightingale JA, Rogers DF, Hart LA, et al. Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax. 1998;53(7):563–571.
36. Kuschner WG, D’Alessandro A, Wong H, et al. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J. 1996;9(10):1989–1994.
37. Clapp WD, Becker S, Quay J, et al. Grain dust-induced airflow obstruction and inflammation of the lower respiratory tract. Am J Respir Crit Care Med. 1994;150(3):611–617.
38. Simpson JL, Guest M, Boggess MM, et al. Occupational exposures, smoking and airway inflammation in refractory asthma. BMC Pulm Med. 2014;14:207.
39. Kreit JW, Gross KB, Moore TB, et al. Ozone-induced changes in pulmonary function and bronchial responsiveness in asthmatics. J Appl Physiol (1985). 1989;66(1):217–222.
40. Scannell C, Chen L, Aris RM, et al. Greater ozone-induced inflammatory responses in subjects with asthma. Am J Respir Crit Care Med. 1996;154(1):24–29.
41. McDonnell WF, Abbey DE, Nishino N, et al. Long-term ambient ozone concentration and the incidence of asthma in nonsmoking adults:the AHSMOG study. Environ Res. 1999;80(2 Pt 1):110–121.
42. Mukae H, Vincent R, Quinlan K, et al. The effect of repeated exposure to particulate air pollution (PM10) on the bone marrow. Am J Respir Crit Care Med. 2001;163(1):201–209.
43. Huttunen R, Heikkinen T, Syrjanen J. Smoking and the outcome of infection. J Intern Med. 2011;269(3):258–269.
44. Green BJ, Wiriyachaiporn S, Grainge C, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One. 2014;9(6):e100645.•• Airway colonization with potentially pathogenic microorganisms is associated with more severe airway obstruction and neutrophilic airway inflammation in patients with treatment-resistant severe asthma.
45. Simpson JL, Daly J, Baines KJ, et al. Airway dysbiosis:Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur Respir J. 2016;47(3):792–800.
46. Johnston SL. The role of viral and atypical bacterial pathogens in asthma pathogenesis. Pediatr Pulmonol Suppl. 1999;18:141–143.
47. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ (Clinical Research Ed.). 1993;307(6910):982–986.
48. Simpson JL, Carroll M, Yang IA, et al. Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids. Chest. 2016;149(3):704–713.
49. Boldogh I, Bacsi A, Choudhury BK, et al. ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation. J Clin Invest. 2005;115(8):2169–2179.
50. Lommatzsch M, Julius P, Kuepper M, et al. The course of allergen-induced leukocyte infiltration in human and experimental asthma. J Allergy Clin Immunol. 2006;118(1):91–97.
51. Kauffman HF, Tomee JF, van de Riet MA, et al. Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production. J Allergy Clin Immunol. 2000;105(6 Pt 1):1185–1193.
52. Blume C, Swindle EJ, Dennison P, et al. Barrier responses of human bronchial epithelial cells to grass pollen exposure. Eur Respir J. 2013;42(1):87–97.
53. Hosoki K, Aguilera-Aguirre L, Brasier AR, et al. Facilitation of allergic sensitization and allergic airway inflammation by pollen-induced Innate neutrophil recruitment. Am J Respir Cell Mol Biol. 2016;54(1):81–90.
54. Trompette A, Divanovic S, Visintin A, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Am J Respir Cell Mol Biol. 2009;457(7229):585–588.
55. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. 2009;15(4):410–416.
56. Hoskins A, Reiss S, Wu P, et al. Asthmatic airway neutrophilia after allergen challenge is associated with the glutathione S-transferase M1 genotype. Am J Respir Crit Care Med. 2013;187(1):34–41.
57. Telenga ED, Tideman SW, Kerstjens HA, et al. Obesity in asthma:more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012;67(8):1060–1068.
58. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224.
59. Scott HA, Gibson PG, Garg ML, et al. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J. 2011;38(3):594–602.
60. Huh JY, Park YJ, Ham M, et al. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells. 2014;37(5):365–371.
61. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight:eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19(8):977–979.
62. Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma:importance and possible mechanisms. Thorax. 2002;57(7):643–648.
63. Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax. 2007;62(3):211–218.
64. Ciencewicki J, Brighton L, Wu WD, et al. Diesel exhaust enhances virus- and poly(I:C)-induced Toll-like receptor 3 expression and signaling in respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;290(6):L1154–1163.
65. Castro SM, Chakraborty K, Guerrero-Plata A. Cigarette smoke suppresses TLR-7 stimulation in response to virus infection in plasmacytoid dendritic cells. Toxicol In Vitro. 2011;25(5):1106–1113.
66. Mortaz E, Adcock IM, Ito K, et al. Cigarette smoke induces CXCL8 production by human neutrophils via activation of TLR9 receptor. Eur Respir J. 2010;36(5):1143–1154.
67. Hernandez ML, Lay JC, Harris B, et al. Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone. J Allergy Clin Immunol. 2010;126(3):537-44.e1.
68. Yang IA, Fong KM, Holgate ST, et al. The role of Toll-like receptors and related receptors of the innate immune system in asthma. Curr Opin Allergy Clin Immunol. 2006;6(1):23–28.
69. Poon AH, Eidelman DH, Martin JG, et al. Pathogenesis of severe asthma. Clin Exp Allergy. 2012;42(5):625–637.
70. Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest. 2008;133(2):420–426.
71. Hoshino H, Laan M, Sjostrand M, et al. Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo. J Allergy Clin Immunol. 2000;105(1 Pt 1):143–149.
72. Michel ML, Keller AC, Paget C, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med. 2007;204(5):995–1001.
73. Simonian PL, Wehrmann F, Roark CL, et al. gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med. 2010;207(10):2239–2253.
74. Ramirez-Velazquez C, Castillo EC, Guido-Bayardo L, et al. IL-17-producing peripheral blood CD177+ neutrophils increase in allergic asthmatic subjects. Allergy Asthma Clin Immunol. 2013;9(1):23.
75. Pelletier M, Maggi L, Micheletti A, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115(2):335–343.• The first evidence that upon activation, human neutrophils, and TH17 cells can directly recruit each other.
76. Bullens DM, Truyen E, Coteur L, et al. IL-17 mRNA in sputum of asthmatic patients:linking T cell driven inflammation and granulocytic influx? Respir Res. 2006;7:135.• Neutrophils mature monocyte-derived dendritic cells to induce T-cell proliferation and polarization toward the Th1 cell phenotype.
77. van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, et al. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med. 2005;201(8):1281–1292.
78. Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (New York, N.Y.). 2002;295(5553):336–338.
79. Kumar RK, Webb DC, Herbert C, et al. Interferon-gamma as a possible target in chronic asthma. Inflamm Allergy Drug Targets. 2006;5(4):253–256.
80. Manni ML, Trudeau JB, Scheller EV, et al. The complex relationship between inflammation and lung function in severe asthma. Mucosal Immunol. 2014;7(5):1186–1198.
81. Raundhal M, Morse C, Khare A, et al. High IFN-gamma and low SLPI mark severe asthma in mice and humans. J Clin Invest. 2015;125(8):3037–3050.
82. Besnard AG, Togbe D, Couillin I, et al. Inflammasome-IL-1-Th17 response in allergic lung inflammation. J Mol Cell Biol. 2012;4(1):3–10.
83. Krishnaswamy JK, Chu T, Eisenbarth SC. Beyond pattern recognition:NOD-like receptors in dendritic cells. Trends Immunol. 2013;34(5):224–233.
84. Simpson JL, Phipps S, Baines KJ, et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J. 2014;43(4):1067–1076.
85. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13(9):1042–1049.
86. Ryckman C, Vandal K, Rouleau P, et al. Proinflammatory activities of S100:proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol. 2003;170(6):3233–3242.
87. Yano J, Kolls JK, Happel KI, et al. The acute neutrophil response mediated by S100 alarmins during vaginal Candida infections is independent of the Th17-pathway. Plos One. 2012;7(9):e46311.
88. Simard JC, Noel C, Tessier PA, et al. Human S100A9 potentiates IL-8 production in response to GM-CSF or fMLP via activation of a different set of transcription factors in neutrophils. FEBS Lett. 2014;588(13):2141–2146.
89. Simard JC, Cesaro A, Chapeton-Montes J, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-kappaB(1.). PLoS One. 2013;8(8):e72138.
90. Lee TH, Song HJ, Park CS. Role of inflammasome activation in development and exacerbation of asthma. Asia Pac Allergy. 2014;4(4):187–196.
91. Lee TH, Jang AS, Park JS, et al. Elevation of S100 calcium binding protein A9 in sputum of neutrophilic inflammation in severe uncontrolled asthma. Ann Allergy Asthma Immunol. 2013;111(4):268-275.e1.•• The first observation on relation of S100A9 with uncontrolled severe asthma and neutrophilic inflammation of the airway.
92. Sugawara S, Uehara A, Nochi T, et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol. 2001;167(11):6568–6575.
93. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science (New York, N.Y.). 2004;303(5663):1532–1535.
94. Baines KJ, Simpson JL, Wood LG, et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol. 2014;133(4):997–1007.
95. Raedler D, Ballenberger N, Klucker E, et al. Identification of novel immune phenotypes for allergic and nonallergic childhood asthma. J Allergy Clin Immunol. 2015;135(1):81–91.
96. Wenzel SE, Balzar S, Cundall M, et al. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9:association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol. 2003;111(6):1345–1352.
97. Cundall M, Sun Y, Miranda C, et al. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol. 2003;112(6):1064–1071.
98. Morjaria JB, Babu KS, Vijayanand P, et al. concentrations in severe asthma and its relationship with FEV1. Thorax. 2011;66(6):537.
99. Simpson JL, Baines KJ, Boyle MJ, et al. Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction. Exp Lung Res. 2009;35(9):781–794.
100. Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol. 1991;4(1):26–32.
101. Bousquet J, Lacoste JY, Chanez P, et al. Bronchial elastic fibers in normal subjects and asthmatic patients. Am J Respir Crit Care Med. 1996;153(5):1648–1654.
102. Monteseirin J, Bonilla I, Camacho MJ, et al. Specific allergens enhance elastase release in stimulated neutrophils from asthmatic patients. Int Arch Allergy Immunol. 2003;131(3):174–181.
103. Pham DN, Chu HW, Martin RJ, et al. Increased matrix metalloproteinase-9 with elastolysis in nocturnal asthma. Ann Allergy Asthma Immunol. 2003;90(1):72–78.
104. Simpson JL, Scott RJ, Boyle MJ, et al. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med. 2005;172(5):559–565.
105. Lee YM, Park JS, Hwang JH, et al. High-resolution CT findings in patients with near-fatal asthma:comparison of patients with mild-to-severe asthma and normal control subjects and changes in airway abnormalities following steroid treatment. Chest. 2004;126(6):1840–1848.
106. Park SW, Park JS, Jeong SH, et al. Air trapping is a major determinant of persistent airway obstruction in asthmatics. Respir Med. 2012;106(6):786–793.
107. Park SW, Park JS, Lee YM, et al. Differences in radiological/HRCT findings in eosinophilic bronchitis and asthma:implication for bronchial responsiveness. Thorax. 2006;61(1):41–47.
108. Ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164(5):744–748.
109. Shaw DE, Berry MA, Hargadon B, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007;132(6):1871–1875.
110. Simpson JL, Milne DG, Gibson PG. Neutrophilic asthma has different radiographic features to COPD and smokers. Respir Med. 2009;103(6):881–887.
111. Busacker A, Newell JD, Jr., Keefe T, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest. 2009;135(1):48–56.• A high level of neutrophils in the airway is a risk factor associated with air trapping in patients with severe asthma.
112. Gupta S, Siddiqui S, Haldar P, et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax. 2010;65(9):775–781.
113. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
114. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma:a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132.
115. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353.e1342.
116. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181(8):788–796.
117. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma:a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):692–701.
118. De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma:a randomized trial. J Allergy Clin Immunol. 2014;133(4):989–996.
119. Yasui K, Hu B, Nakazawa T, et al. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest. 1997;100(7):1677–1684.
120. Chung IY, Nam-Kung EK, Lee NM, et al. The downregulation of Bcl-2 expression is necessary for theophylline-induced apoptosis of eosinophil. Cell Immunol. 2000;203(2):95–102.
121. Nielson CP, Crowley JJ, Morgan ME, et al. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3ʹ,5ʹ-adenosine monophosphate. Am Rev Respir Dis. 1988;137(1):25–30.
122. Yasui K, Agematsu K, Shinozaki K, et al. Effects of theophylline on human eosinophil functions:comparative study with neutrophil functions. J Leukoc Biol. 2000;68(2):194–200.
123. Kraft M, Torvik JA, Trudeau JB, et al. Theophylline:potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol. 1996;97(6):1242–1246.
124. Culpitt SV, de Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(10):1371–1376.
125. Kraft M, Pak J, Borish L, et al. Theophylline’s effect on neutrophil function and the late asthmatic response. J Allergy Clin Immunol. 1996;98(2):251–257.
126. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest. 2005;128(4):1936–1942.
127. Reid DW, Ward C, Wang N, et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J. 2003;21(6):994–999.
128. Theron AJ, Steel HC, Tintinger GR, et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res Ther. 2014;608930:2014.
129. Braido F, Riccio AM, Rogkakou A, et al. Montelukast effects on inflammation in allergic rhinitis:a double blind placebo controlled pilot study. Eur Ann Allergy Clin Immunol. 2012;44(2):48–53.
130. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–155.
131. Kew KM, Undela K, Kotortsi I, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;9:Cd002997.
132. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST):a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329.
133. Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, et al. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010;126(4):754–762.e751.
134. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease:findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727.
135. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23(5):729–736.
136. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273(37):24266–24271.
137. Matsuno H, Takei M, Hayashi H, et al. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol. 2004;43(3):333–340.
138. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database of Systematic Reviews 1998:published online 26 July 1998, DOI:10.1002/14651858.CD000391
139. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235–256.
140. Sanz MJ, Cortijo J, Morcillo EJ. PDE4 inhibitors as new anti-inflammatory drugs:effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther. 2005;106(3):269–297.
141. Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils:a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103.
142. Leaker BR, Barnes PJ, O’Connor B. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res. 2013;14:137.
143. Hernandez ML, Wagner JG, Kala A, et al. Vitamin E, gamma-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers. Free Radic Biol Med. 2013;60:56–62.
144. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302.
145. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354(7):697–708.• The TNF-α antagonist etanercept is associated with significant improvement in airway responsiveness and airflow obstruction in patients with severe asthma.
146. Michel O, Dinh PH, Doyen V, et al. Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human. BMC Pharmacol Toxicol. 2014;15:60.
147. Hernandez ML, Mills K, Almond M, et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol. 2015;135(2):379–385.•• An IL-1 receptor antagonist (anakinra) significantly reduced LPS-induced IL-1β, IL-6, and IL-8 levels in conjunction with inhaled LPS, with concomitant attenuation of airway neutrophilic inflammation in a model of inhaled LPS challenge.
148. Zeki AA, Oldham J, Wilson M, et al. Statin use and asthma control in patients with severe asthma. BMJ Open. 2013;3:8.
149. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function:VA normative aging study. Am J Respir Crit Care Med. 2007;176(8):742–747.
150. Thomson NC, Charron CE, Chaudhuri R, et al. Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulm Pharmacol Ther. 2015;31:1–8.
151. Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med. 1990;112(8):577–581.
152. Braber S, Overbeek SA, Koelink PJ, et al. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1. Eur J Pharmacol. 2011;668(3):443–449.
153. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179(7):549–558.